ACE2 and pulmonary hypertension: The early stages of in vitro SARS-CoV-2 infection can be suppressed by human recombinant soluble ACE2, which has been studied in clinical trials for the management of acute pulmonary injury and pulmonary hypertension, indicating that therapeutic agents acting on the ACE2 pathway may have a beneficial role in the management of COVID-19 infection [116].